Viewing Study NCT04198766


Ignite Creation Date: 2025-12-24 @ 4:39 PM
Ignite Modification Date: 2025-12-24 @ 4:39 PM
Study NCT ID: NCT04198766
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-18
First Post: 2019-12-11
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Sponsor: Inhibrx Biosciences, Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module